Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Black Diamond Therapeutics (BDTX) Enterprise Value (2018 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Enterprise Value for 3 consecutive years, with -$235.0 million as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Enterprise Value rose 29.44% year-over-year to -$235.0 million, compared with a TTM value of -$235.0 million through Sep 2021, up 29.44%, and an annual FY2020 reading of -$315.1 million, down 103.71% over the prior year.
  • Enterprise Value was -$235.0 million for Q3 2021 at Black Diamond Therapeutics, up from -$263.5 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$39.6 million in Q2 2019 and bottomed at -$357.2 million in Q1 2020.
  • Average Enterprise Value over 3 years is -$210.5 million, with a median of -$235.0 million recorded in 2021.
  • The sharpest move saw Enterprise Value crashed 698.78% in 2020, then rose 29.44% in 2021.
  • Year by year, Enterprise Value stood at -$154.7 million in 2019, then plummeted by 103.71% to -$315.1 million in 2020, then increased by 25.41% to -$235.0 million in 2021.
  • Business Quant data shows Enterprise Value for BDTX at -$235.0 million in Q3 2021, -$263.5 million in Q2 2021, and -$290.1 million in Q1 2021.